Literature DB >> 7273603

Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.

P Sandor, E M Sellers, M Dumbrell, V Khouw.   

Abstract

Phenytoin kinetics during long-term alcohol use and withdrawal were studied in 11 male alcoholics with a history of withdrawal seizures and no evidence of chronic liver disease. Ethanol, 20% v/v, was given for 6 days after admission to maintain the blood alcohol level between 500 and 800 mg/l and phenytoin suspension, 150 mg, was given orally or intravenously (on three occasions) every 12 hr for 20 days. The mean (+/- SD) total phenytoin clearance in 9 of 11 subjects was 0.023 +/- 0.006 l/kg/hr during the alcohol ingestion period. Clearance rose to 0.033 +/- 0.013 l/kg/hr (P less than 0.05) during alcohol withdrawal. Total steady-state concentration after 3 wk ranged from 3.4 to 29.9 mg/l, while the weight-corrected dose range was only 3.7 to 5.5 mg/kg/day. Inter- and intra-subject variation in bioavailability was small (0.93 to 1.03). Phenytoin free fractions ranged from 9.09% to 17.75% and changes in total and free phenytoin concentration correlated (r2 = 0.92, P less than 0.001). The data are compatible with the hypothesis that increased phenytoin clearance during alcohol withdrawal is due to the increased metabolic rate of the drug secondary to enzyme induction by ethanol, which becomes unmasked on cessation of drinking. In most alcoholics standard-dose phenytoin (300 mg/l) will induce lower than usual plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273603     DOI: 10.1038/clpt.1981.178

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 3.  Effects of ethanol on drug and metabolite pharmacokinetics.

Authors:  E A Lane; S Guthrie; M Linnoila
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 4.  Epilepsy in the elderly.

Authors:  Ilo E Leppik; Angela K Birnbaum
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 5.  Epilepsy in the elderly.

Authors:  I E Leppik
Journal:  Curr Neurol Neurosci Rep       Date:  2001-07       Impact factor: 5.081

6.  Carbamazepine kinetics and adverse effects during and after ethanol exposure in alcoholics and in healthy volunteers.

Authors:  B Sternebring; A Lidén; K Andersson; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management.

Authors:  E M Sellers
Journal:  CMAJ       Date:  1988-07-15       Impact factor: 8.262

Review 8.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

9.  Exploring the Interactome of Cytochrome P450 2E1 in Human Liver Microsomes with Chemical Crosslinking Mass Spectrometry.

Authors:  Dmitri R Davydov; Bikash Dangi; Guihua Yue; Deepak S Ahire; Bhagwat Prasad; Victor G Zgoda
Journal:  Biomolecules       Date:  2022-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.